Biophar Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 08-07-2024
- Paid Up Capital ₹ 3.45 M
as on 08-07-2024
- Company Age 14 Year, 2 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 65.83 M
as on 08-07-2024
- Revenue 21.15%
(FY 2022)
- Profit 19.16%
(FY 2022)
- Ebitda 85.60%
(FY 2022)
- Net Worth 16.24%
(FY 2022)
- Total Assets 14.28%
(FY 2022)
About Biophar Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.45 M.
The company currently has active open charges totaling ₹6.58 Cr.
Sunita and Gulshan Rawat serve as directors at the Company.
- CIN/LLPIN
U24132CH2010PTC032343
- Company No.
032343
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jul 2010
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Biophar Lifesciences Private Limited offer?
Biophar Lifesciences Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Respiratory System Drugs, Anti Asthma Drug, Anti Infective Drugs & Medicines, Antibacterial Drugs, Cardiovascular Drugs & Medication, Diabetes Medicine, Malaria Medicine, Industrial Chemicals & Supplies.
Who are the key members and board of directors at Biophar Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunita  | Director | 21-Jan-2023 | Current |
| Gulshan Rawat | Director | 16-Jul-2010 | Current |
Financial Performance and Corporate Structure Insights of Biophar Lifesciences.
Biophar Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 21.15% increase. The company also saw a substantial improvement in profitability, with a 19.16% increase in profit. The company's net worth Soared by an impressive increase of 16.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biophar Lifesciences?
In 2022, Biophar Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 21 Dec 2023 | ₹2.00 Cr | Open |
Others Creation Date: 27 Apr 2023 | ₹8.07 M | Open |
Others Creation Date: 28 Nov 2022 | ₹2.20 Cr | Open |
How Many Employees Work at Biophar Lifesciences?
Biophar Lifesciences has a workforce of 4 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Aug 15, 2013, Biophar Lifesciences has raised a total of ₹ 6.3 M, with the most recent deal valued at ₹ 3.15 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
